Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Journal of Pharmacokinetics and Pharmacodynamics|April 28, 2016
Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritisXi Chen, Xiling Jiang, William J Jusko, et al.Journal of Pharmaceutical Sciences|July 8, 2023
Quantitative Systems Pharmacology for Rare Disease Drug DevelopmentJane Pf Bai, Jie Wang, Yifei Zhang, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 15, 2020
Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humansXiling Jiang, Xi Chen, Pharavee Jaiprasart, et al.Pharmaceutical Research|January 1, 2016
Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis ModelWeirong Wang, Thomas S McIntosh, Xiling Jiang, et al.3 Biotech|May 5, 2026
Causal effect of gut <i>Streptococcus</i> abundance on maternal genitourinary infection during pregnancy: a two-sample Mendelian randomization studyRihan Wu, Baoyin Batu, Jargalsaikhan Badarch, et al.American Journal of Translational Research|December 14, 2020
Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinomaChanggang Guo, Ting Shao, Xiling Jiang, et al.The Journal of Pharmacology and Experimental Therapeutics|February 9, 2018
Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like MiceXi Chen, Xiling Jiang, Rajitha Doddareddy, et al.Mabs|July 10, 2018
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agentsXiling Jiang, Xi Chen, Thomas J Carpenter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2025
FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase ChemotherapyCara A Rabik, Shu Wang, Ritu Chadda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2023
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 MutationAshley Woods, Kelly J Norsworthy, Xin Wang, et al.Pageof 3